[1] |
Hoffman EP. Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies[J]. Acta Myol, 2020, 394(4): 179-186.
|
[2] |
Aslesh T, Erkut E, Yokota T. Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing[J]. Expert Opin Biol Ther, 2021, 21(8): 1049-1061.
doi: 10.1080/14712598.2021.1872539
|
[3] |
Ma P, Zhang S, Zhang H, et al. Comprehensive genetic characteristics of dystrophinopathies in China[J]. Orphanet J Rare Dis, 2018, 13(1): 109.
doi: 10.1186/s13023-018-0853-z
|
[4] |
Kwon JB, Ettyreddy AR, Vankara A, et al. In vivo gene editing of muscle stem cells with adeno-associated viral vectors in a mouse model of Duchenne muscular dystrophy[J]. Mol Ther Methods Clin Dev, 2020, 19: 320-329.
doi: 10.1016/j.omtm.2020.09.016
|
[5] |
Mata López S, Balog-Alvarez C, Vitha S, et al. Correction: challenges associated with homologous directed repair using CRISPR-Cas9 and TALEN to edit the DMD genetic mutation in canine Duchenne muscular dystrophy[J]. PLoS One, 2020, 15(10): e0241430.
doi: 10.1371/journal.pone.0241430
|
[6] |
Schneider AE, Aartsma-Rus A. Developments in reading frame restoring therapy approaches for Duchenne muscular dystrophy[J]. Expert Opin Biol Ther, 2021, 21(3): 343-359.
doi: 10.1080/14712598.2021.1832462
|
[7] |
胡亚美, 江载芳, 申昆玲, 等. 诸福棠实用儿科学(下册) [M]. 8版. 北京: 人民卫生出版社, 2015: 2526-2530.
|
[8] |
Richards S, Aziz N, Bale S, et al. standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424.
doi: 10.1038/gim.2015.30
pmid: 25741868
|
[9] |
Tyagi R, Arvind H, Goyal M, et al. Working memory alterations plays an essential role in developing global neuropsychological impairment in Duchenne muscular dystrophy[J]. Front Psychol, 2021, 11: 613242.
doi: 10.3389/fpsyg.2020.613242
|
[10] |
Hellebrekers DMJ, Vles JSH, Klinkenberg S, et al. The neurocognitive and behavioral profiles of 3 brothers with Becker muscular dystrophy [J]. Child Neurol Open, 2020, 7: 2329048X20957217.
|
[11] |
Sanchez F, Weitz C, Gutierrez JM, et al. Cardiac MR imaging of muscular dystrophies[J]. Curr Probl Diagn Radiol, 2022, 51(2): 225-234.
doi: 10.1067/j.cpradiol.2020.12.010
|
[12] |
Lim KRQ, Nguyen Q, Yokota T. Genotype-phenotype correlations in Duchenne and Becker muscular dystrophy patients from the Canadian neuromuscular disease registry[J]. J Pers Med, 2020, 10(4): 241.
doi: 10.3390/jpm10040241
|
[13] |
Tong YR, Geng C, Guan YZ, et al. A comprehensive analysis of 2013 dystrophinopathies in China: a report from National Rare Disease Center[J]. Front Neurol, 2020, 11: 572006.
doi: 10.3389/fneur.2020.572006
|
[14] |
Juan-Mateu J, Gonzalez-Quereda L, Rodriguez MJ, et al. DMD mutations in 576 dystrophinopathy families: a step forward in genotype-phenotype correlations[J]. PLoS One, 2015, 10(8): e0135189.
doi: 10.1371/journal.pone.0135189
|
[15] |
Tawalbeh S, Samsel A, Gordish-Dressman H, et al. Comparison of serum pharmacodynamic biomarkers in prednisone-versus deflazacort-treated Duchenne muscular dystrophy boys[J]. J Pers Med, 2020, 10(4): 164.
doi: 10.3390/jpm10040164
|
[16] |
Merlini L, Cecconi I, Parmeggiani A, et al. Quadriceps muscle strength in Duchenne muscular dystrophy and effect of corticosteroid treatment[J]. Acta Myol, 2020, 39(4): 200-206.
|
[17] |
Sussman MD, Sienko SE, Buckon CE, et al. Efficacy of corticosteroid in decreasing scoliosis and extending time to loss of ambulation in a single clinic: an effectiveness trial[J]. J Child Orthop, 2020, 14(5): 421-432.
doi: 10.1302/1863-2548.14.200156
|
[18] |
Wood CL, Hollingsworth KG, Hughes E, et al. Pubertal induction in adolescents with DMD is associated with high satisfaction, gonadotropin release and increased muscle contractile surface area[J]. Eur J Endocrinol, 2021, 184(1): 67-79.
doi: 10.1530/EJE-20-0709
|
[19] |
Panovský R, Pešl M, Máchal J, et al. Quantitative assessment of left ventricular longitudinal function and myocardial deformation in Duchenne muscular dystrophy patients[J]. Orphanet J Rare Dis, 2021, 16(1): 57.
doi: 10.1186/s13023-021-01704-9
pmid: 33516230
|
[20] |
Mayer OH. The impact of corticosteroids on cardio-pulmonary progression in Duchenne muscular dystrophy[J]. Chest, 2020, 158(5): 1827-1828.
doi: 10.1016/j.chest.2020.05.517
|
[21] |
Santos ALYDS, Maciel FKL, Fávero FM, et al. Trunk control and upper limb function of walking and non-walking Duchenne muscular dystrophy individuals[J]. Dev Neurorehabil, 2021, 24(7): 435-441.
doi: 10.1080/17518423.2020.1869337
|
[22] |
Lobo-Prat J. Enkaoua A, Rodriguez-Fernández A, et al. Evaluation of an exercise-enabling control interface for powered wheelchair users: a feasibility study with Duchenne muscular dystrophy[J]. J Neuroeng Rehabil, 2020, 17(1): 142.
doi: 10.1186/s12984-020-00760-9
|
[23] |
Beckers P, Caberg JH, Dideberg V, et al. Newborn screening of duchenne muscular dystrophy specifically targeting deletions amenable to exon-skipping therapy[J]. Sci Rep, 2021, 11(1): 3011.
doi: 10.1038/s41598-021-82725-z
pmid: 33542429
|
[24] |
Ng MY, Li H, Ghelfi MD, et al. Ataluren and ami-noglycosides stimulate read-through of nonsense codons by orthogonal mechanisms[J]. Proc Natl Acad Sci U S A, 2021, 118(2): e2020599118.
doi: 10.1073/pnas.2020599118
|
[25] |
Hanson B, Wood MJA, Roberts TC, et al. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing[J]. RNA Biol, 2021, 18(7): 1048-1062.
doi: 10.1080/15476286.2021.1874161
|
[26] |
Anwar S, He M, Lim KRQ, et al. DMDA genotype-phenotype correlation study of exon skip-equivalent in-frame deletions and exon skip-amenable out-of-frame deletions across the DMD gene to simulate the effects of exon-skipping therapies: a meta-analysis[J]. J Pers Med, 2021, 11(1): 46.
doi: 10.3390/jpm11010046
|
[27] |
Mendell JR, Khan N, Sha N, et al. Comparison of long-term ambulatory function in patients with Duchenne muscular dystrophy treated with eteplirsen and matched natural history controls[J]. J Neuromuscul Dis, 2021, 8(4): 469-479.
doi: 10.3233/JND-200548
pmid: 33523015
|
[28] |
Scaglioni D, Catapano F, Ellis M, et al. The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy[J]. Acta Neuropathol Commun, 2021, 9(1): 7.
doi: 10.1186/s40478-020-01106-1
|
[29] |
Zeng B, Zhou M, Liu B, et al. Targeted addition of mini-dystrophin into rDNA locus of Duchenne muscular dystrophy patient-derived iPSCs[J]. Biochem Biophys Res Commun, 2021, 545: 40-45.
doi: 10.1016/j.bbrc.2021.01.056
|
[30] |
Sheikh O, Yokota T. Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies[J]. Expert Opin Investig Drugs, 2021, 30(2): 167-176.
doi: 10.1080/13543784.2021.1868434
|